Imetelstat in patients with lower-risk MDS Published 2023-12-24 Download video MP4 360p Recommendations 55:44 Low Risk vs High Risk MDS - What's the Difference? 05:37 Panel Discusses New Data on Emerging Therapies in MDS: Imetelstat, KER-050, and More 55:02 Acute and Late Toxicities of Bi-specific Antibody Therapy 03:38 How serious a cancer is MDS? What is the prognosis for MDS? 28:59 Stefanie Faye | Neuro-Mechanics of Mindset: How our Past Affects the Present | Talks at Google 1:16:04 Post ASH23 Myeloma roundtable by the IACH 1:24:50 Geoffrey Moore on finding your beachhead, crossing the chasm, and dominating a market 39:02 Trust Deterministic Execution to Scale & Simplify Your Systems • Frank Yu • YOW! 2023 1:08:17 Roman Orus - News on tensor Networks for machine learning and quantum computing simulation 18:34 Dr. Devi Shetty | Cost of Healthcare | Doing Business in India | Mastering India 13:39 Key highlights in MDS: treating lower-risk & higher-risk disease, trial updates, and more 1:25:53 Live from ASH23 Dec 12 2023 24:11 Assassins, plots and chaos: How Malcolm Turnbull was brought down | Nemesis 54:02 Management of High-Risk Chronic Lymphocytic Leukemia 32:01 The Surprising Link Between Intermittent Fasting, Diabetes, and Cancer. Dr. Jason Fung Explains PT 1 46:37 Java Renaissance • Georges Saab • YOW! 2023 19:41 Living with A Rare Blood Cancer, Polycythemia Vera 02:51 Analysis of the IMerge trial: the disease-modifying potential of imetelstat in LR-MDS 57:51 My Advice to Early Career Group Therapists: Irvin Yalom, MD, DLFAGPA 1:09:55 The ultimate guide to JTBD | Bob Moesta (co-creator of the framework) Similar videos 01:25 IMerge subgroup study: imetelstat in patients with LR-MDS previously exposed to ESAs 02:40 IMerge results: efficacy and disease-modifying activity of imetelstat in LR-MDS after ESA failure 02:19 Imetelstat for transfusion-dependent R/R MDS 01:44 IMerge update: continuous transfusion independence & disease modification with imetelstat in LR-MDS 04:12 Novel therapies in low-risk MDS 04:10 Does imetelstat provide transfusion independence in lower-risk MDS? 02:57 Imetelstat for LR-MDS: insights from the IMerge trial 03:46 Promising agents under investigation for low and high-risk MDS 03:08 hTERT reduction by imetelstat correlates with clinical activity in MDS 09:38 Imetelstat provides durable transfusion independence in lower risk MDS group 02:38 Imetelstat on-target activity correlates with clinical benefits in MDS: IMerge findings 01:34 Managing adverse events with novel therapies in lower-risk MDS 03:12 Prolonged & continuous transfusion independence after imetelstat treatment in the IMerge trial 02:12 Improving the treatment of low-risk MDS: luspatercept, treatment sequencing & disease classification 04:32 Recent advances in the treatment of LR-MDS: COMMANDS and IMerge trial data 03:50 Imetelstat efficacy is independent of molecular subtypes in R/R LR-MDS 01:27 Key clinical trials in high-risk and low-risk MDS 11:53 The optimal treatment of lower risk MDS More results